Skip Navigation LinksHome > July 2013 - Volume 20 - Issue 7 > Effects of adding alendronate to ongoing hormone therapy on...
Menopause:
doi: 10.1097/GME.0b013e31827b24af
Original Articles

Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial

Min, Yong-Ki MD, PhD1; Lee, Dong-Yun MD, PhD2; Choi, Suk-Joo MD, PhD2; Kim, Joo Han PhD3; Choi, DooSeok MD, PhD2; Yoon, Byung-Koo MD, PhD2

Collapse Box

Abstract

Objective

This study was conducted to evaluate the effects of adding the bisphosphonate alendronate (ALEN) to ongoing hormone therapy (HT) on bone mineral density (BMD) in postmenopausal Korean women.

Methods

This randomized, double-blind, placebo-controlled clinical trial at a university hospital included a total of 139 postmenopausal women who had low BMD after HT lasting at least 1 year. Women received either ALEN (10 mg/d) or placebo in combination with HT for 1 year. Changes in BMD and biochemical markers of bone turnover were evaluated.

Results

Lumbar spine and total hip BMDs increased significantly in both treatment groups after 1 year. The addition of ALEN, when compared with HT alone, did not produce a significant change in BMD at the lumbar spine (3.7% vs 4.3%) and total hip (2.2% vs 3.2%) after adjusting for controllable variables. Serum osteocalcin showed a similar change, but urinary deoxypyridinoline response differed between treatment groups.

Conclusions

Compared with HT alone, the addition of ALEN to ongoing HT for 1 year does not make a difference in BMD among postmenopausal Korean women with low BMD.

© 2013 by The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.